DISCLAIMER

Electronic versions of the exhibits in these minutes may not be complete.

This information is supplied as an informational service only and should not be relied upon as an official record.

Original exhibits are on file at the Legislative Counsel Bureau Research Library in Carson City.

Contact the Library at (775) 684-6827 or library@lcb.state.nv.us.

AMENDMENT		
ADD		
Section 5, subsection 2, page 2, line 7		
The prior authorization is done by the prescriber and not by the pharmacy.		

NEW LANGUAGE

Section 5, subsection 2

Require prior authorization before the prescription drug may be provided. The prior authorization is done by the prescriber and not by the pharmacy.

PURPOSE

Since the prescriber determines what drug is dispensed, it seems logical that the prescriber would be responsible for checking the preferred drug list. Pharmacists can then focus on counseling the patients on the use of the drug rather than spend time on the telephone with the doctor's office trying to get the switch approved.

ASSEMBLY, HEALTH AND HUMAN SERVICES
DATE: 04/07 ROOM: 3/38 EXHIBIT F/-8
SUBMITTED BY: Mary Staples

AMENDMENT		

DELETE

Section 6, subsection 2, (a), page 2, line 12, (a)

Six

Section 6, subsection 2, (b), page 2, line 14

Four

NEW LANGUAGE

Section 6, subsection 2, (a) & (b)

- (a) Five members who are physicians licensed to practice medicine in this state;
- (b) Five members who are pharmacists registered in this state, one who must have a doctoral degree in pharmacy and be employed by a hospital licensed in this state, and one who must have a doctoral degree in pharmacy and be employed by a retail pharmacy licensed in this state; and

PURPOSE

Professional parity. Most states PDL committees have an equal number of pharmacists and physicians.

AMENDMENT
DELETE
Section 7, subsection 4, on page 2, line 39
every 6 months
ADD
Section 7, subsection 4, on page 2, line 39
<u>a quarter</u>
NEW LANGUAGE

The Committee shall meet at least once a quarter and at the times and places specified by a call of the Chairman of the Committee.

PURPOSE

Section 7, subsection 4

It is important for this committee to meet more often than twice a year to consider new drug therapies so the preferred drug list can be kept current.

AMENDN	1ENT
---------------	------

DELETE

Section 9, subsection 5, on page 3, lines 30-33

5. Advise the Department concerning the negotiation of supplemental rebates and other program benefits with manufacturers of prescription drugs pursuant to section 12 of this act;

PURPOSE

The focus of the P&T Committee should be on selecting the best drug in the class based on sound clinical analysis to be put on the preferred drug list, not to negotiate prices. The department and/or a third party administrator should negotiate the rebates with manufacturers.

A	MEN	IDMEN	T
---	-----	-------	---

DELETE

Section 9, subsection 6, on page 3, lines 30-33

6. Ensure that a manufacturer of prescription drugs who agrees to provide a supplemental rebate or other program benefit to the Department pursuant to section 12 of this act has an opportunity to present evidence which supports the inclusion of its prescription drugs on the list of preferred prescription drugs developed by the Department pursuant to section 11 of this act; and

PURPOSE

In order to achieve success, we need to keep the integrity of the process intact. Committee members do not need to be lobbied on what drugs to add to the preferred drug list. Sound clinical judgment, peer review articles and published studies should provide the P&T Committee with enough information.

AN.	IEND	MENT	

DELETE

Section 9, subsection 7, on page 3, lines 44 & 45

-equipment and supplies for the treatment of diabetes,

Section 9, subsection 7, on pages 3, lines 44 & 45, and on page 4, lines 2-4

prescription drugs that are prescribed for a person with a mental illness, and prescription drugs for family planning and birth control.

ADD

Section 9, subsection 7, on page 4, line 4

and atypical antipsychotic drugs.

NEW LANGUAGE

Section 9, subsection 7

7. Identify prescription drugs which should be exempt from the requirements of section 5 of this act because a change of a prescription of a patient might be detrimental to the patient, including, without limitation, prescription drugs antiretroviral prescription drugs that are prescribed for a person infected with the human immunodeficiency virus, and atypical antipsychotic drugs.

PURPOSE

Carve outs undermine the program and should be limited. Most states PDL programs typically carve out antiretroviral and atypical antipsychotic drugs. Medical equipment and supplies needs to be deleted because it is not part of the Medicaid drug budget. Diabetes drugs are a top spend category and should be reviewed by the P&T Committee. The more carve outs, the few drug dollars are saved.

AMENDMENT
DELETE
Section 10, subsection 1, on page 4, lines 6-8
1. Apply for and accept any gift, donation, bequest, grant or other source of mone to aid the Committee in carrying out its duties;
PURPOSE
This section is unnecessary. We need to uphold the integrity of the committee.

A	MEND	MENT	
---	-------------	------	--

DELETE

Section 10, subsection 4, on page 4, lines 13-14

4. Conduct investigations and hold hearings in connection with its review and analysis; and

PURPOSE

The P & T Committee members should debate openly at public meetings, but there is no need to have witnesses provide testimony. There exists so much published clinical data on these top spend drugs. Holding hearings would only slow the process and jeopardize achieving cost savings from the program.